AlphAIAlphAI — Financial news for AI agents
marketscreener.comSEP 171 min read$BSX

Citigroup Downgrades Boston Scientific to Neutral From Buy, Adjusts Price Target to $50 From $57

Citigroup downgraded Boston Scientific to 'Neutral' from 'Buy' and reduced its price target to $50 from $57. The stock has seen a 5-day change of +0.09%, a 1st Jan change of -2.34%, and a 52-week change of -53.95%.

Original reporting
marketscreener.com
Published Sep 17, 2026, 9:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 10:22 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$BSX
Bearish
medium confidence
Mentioned
$BSX
Relevance
6/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

$BSXBearishHigh
01

Why it matters

The downgrade may trigger short‑term selling pressure, but longer‑term fundamentals remain unchanged.

02

Market read

Analyst rating change is a direct catalyst for BSX price movement.

03

What to watch

Potential upside from recent FDA approvals not mentioned in the downgrade note.

Relevance 6/10Novelty 7/10Timing: pre‑market today

Background

Citigroup issued a rating change for Boston Scientific, adjusting its valuation outlook.

Company-level read

Ticker impact

$BSXBearishMedium confidence
Context

Citigroup downgraded Boston Scientific to Neutral and cut its price target to $50 from $57.

Expected impact

Potential short‑term price decline of 3‑5% as investors adjust expectations.

Evidence & confidence

Downgrades historically trigger sell‑offs, especially with a lower price target; no other catalyst is mentioned.

Market effects

Sector

May weigh on other med‑tech stocks as analysts reassess valuation multiples.

Regional

Limited to U.S. healthcare sector; no broader regional effect.

Global

Minimal global impact beyond U.S. investors.

Counterpoint

What could challenge this read

The downgrade could be premature if upcoming product launches exceed expectations.

Key entities

  • Company
    Boston Scientific

    Medical device manufacturer (ticker BSX).

  • Research Firm
    Citigroup

    Equity research analyst providing the downgrade.

Read at source← All news

Also covered by

1 outlet

Related articles

SEP 13
$BSXHigh

Boston Scientific (BSX) Didn’t Miss on Demand or Devices. A Cyberattack Just Broke Its Guidance.

Boston Scientific (BSX) fell 2.3% after a cyberattack disrupted operations, leading to a guidance cut for Q3 and 2026. The attack caused shipping delays, not demand issues, and the company expects recovery. BSX faces competitive pressure in the electrophysiology market. Hedge fund holdings decreased slightly, with low short interest. The company's long-term outlook remains intact, but near-term visibility is weak.

yahoo.com2 min
SEP 10
$BSXMed

When is a business really recovered from a cyberattack?

Boston Scientific's cyberattack disrupted operations, and while most systems are restored, the company expects material financial impacts on Q3 and full-year results, likely missing sales and profit forecasts. Experts discuss the complexity of defining business recovery post-cyberattack, emphasizing the need to align IT recovery with business outcomes and prioritize critical processes.

informationweek.com3 min